title: CCR5Δ32 Polymorphism Associated with a Slower Rate Disease Progression in a Cohort of RR-MS Sicilian Patients.
abstract: Multiple sclerosis (MS) disease is carried through inflammatory and degenerative stages. Based on clinical feaures, it can be subdivided into three groups: relapsing-remitting MS, secondary progressive MS, and primary progressive MS. Multiple sclerosis has a multifactorial etiology with an interplay of genetic predisposition, environmental factors, and autoimmune inflammatory mechanism in which play a key role CC-chemokines and its receptors. In this paper, we studied the frequency of CCR5 gene Δ32 allele in a cohort of Sicilian RR-MS patients comparing with general Sicilian population. Also, we evaluate the association between this commonly polymorphism and disability development and age of disease onset in the same cohort. Our results show that presence of CCR5Δ32 is significantly associated with expanded disability status scale score (EDSS) but not with age of disease onset.
authors.affiliation: Department of Biomorphology and Biotechnologies, University of Messina, 98125 Messina, Italy.
authors.forename: Rosalia
authors.initials: R
authors.lastname: D'Angelo
authors.forename: Concetta
authors.initials: C
authors.lastname: Crisafulli
authors.forename: Carmela
authors.initials: C
authors.lastname: Rinaldi
authors.forename: Alessia
authors.initials: A
authors.lastname: Ruggeri
authors.forename: Aldo
authors.initials: A
authors.lastname: Amato
authors.forename: Antonina
authors.initials: A
authors.lastname: Sidoti
references.citation: Mult Scler. 2005 Oct;11(5):504-10
references.pmid: 16193885
references.citation: J Exp Med. 1998 Jan 5;187(1):129-34
references.pmid: 9419219
references.citation: J Neuroimmunol. 1999 Jul 1;98(1):57-68
references.pmid: 10426363
references.citation: Neurosci Lett. 2002 Sep 27;330(3):293-5
references.pmid: 12270649
references.citation: Eur J Hum Genet. 2005 Feb;13(2):240-7
references.pmid: 15494740
references.citation: Brain Res Bull. 2003 Aug 15;61(3):347-55
references.pmid: 12909304
references.citation: J Neuroimmunol. 2000 Jan 3;102(1):98-106
references.pmid: 10626673
references.citation: Lancet. 2002 Apr 6;359(9313):1221-31
references.pmid: 11955556
references.citation: Int J Immunogenet. 2005 Jun;32(3):193-8
references.pmid: 15932625
references.citation: Immunogenetics. 2000 Apr;51(4-5):281-8
references.pmid: 10803840
references.citation: J Neuroimmunol. 2002 Dec;133(1-2):225-32
references.pmid: 12446027
references.citation: Am J Pathol. 1997 Nov;151(5):1341-51
references.pmid: 9358760
references.citation: Ann Neurol. 1983 Mar;13(3):227-31
references.pmid: 6847134
references.citation: Mult Scler. 2004 Apr;10(2):149-52
references.pmid: 15124759
references.citation: Hum Biol. 2006 Jun;78(3):371-8
references.pmid: 17216809
references.citation: Neurogenetics. 2007 Aug;8(3):201-5
references.pmid: 17351762
references.citation: J Neurovirol. 1999 Feb;5(1):102-8
references.pmid: 10190696
references.citation: J Neuroimmunol. 2000 Aug 1;108(1-2):192-200
references.pmid: 10900353
references.citation: Int J Mol Med. 2007 Sep;20(3):337-44
references.pmid: 17671738
references.citation: J Immunol. 1999 Oct 1;163(7):3653-61
references.pmid: 10490959
references.citation: Acta Neurol Scand. 2007 Jun;115(6):413-8
references.pmid: 17511851
references.citation: J Neurol Sci. 2005 Feb 15;228(2):210-4
references.pmid: 15694210
references.citation: J Neuroimmunol. 2008 Sep 15;201-202:183-99
references.pmid: 18632165
references.citation: Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12877-82
references.pmid: 14569025
references.citation: Cell. 1996 Aug 9;86(3):367-77
references.pmid: 8756719
references.citation: Cell Mol Neurobiol. 2009 Dec;29(8):1205-9
references.pmid: 19479371
references.citation: Acta Neurol Scand. 2003 Dec;108(6):396-400
references.pmid: 14616291
references.citation: Acta Neurol Scand Suppl. 2008;188:34-40
references.pmid: 18439219
references.citation: Ann Neurol. 2000 Feb;47(2):269-73
references.pmid: 10665504
references.citation: Nature. 1996 Jun 20;381(6584):661-6
references.pmid: 8649511
references.citation: Mult Scler. 2006 Jun;12(3):360-2
references.pmid: 16764352
references.citation: Nat Immunol. 2001 Feb;2(2):108-15
references.pmid: 11175802
references.citation: Neurology. 2003 Jul 22;61(2):238-40
references.pmid: 12874407
references.citation: J Neuroimmunol. 2005 Dec;169(1-2):137-43
references.pmid: 16182378
references.citation: Brain Res Brain Res Rev. 2005 Feb;48(1):16-42
references.pmid: 15708626
references.citation: Acta Clin Croat. 2009 Sep;48(3):349-53
references.pmid: 20055262
references.citation: Nature. 1996 Aug 22;382(6593):722-5
references.pmid: 8751444
references.citation: CNS Neurol Disord Drug Targets. 2008 Dec;7(6):536-57
references.pmid: 19128210
references.citation: Pharmacol Ther. 2005 May;106(2):163-77
references.pmid: 15866318